We confirmed the antitumor activity of COL11A1-CAR T cells using our subcutaneous EWS (A673) model41 in which tumor-bearing mice received one single i.v. dose of 1 × 106 COL11A1-CAR or NT T cells on day 7 (Fig. 4F). This evidence concerns the gene COL11A1 and neoplasm.